AB-103 is under clinical development by Jupiter Wellness and currently in Phase II for Alopecia. According to GlobalData, Phase II drugs for Alopecia have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AB-103’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AB-103 is under development for the treatment of alopecia. It is administered by topical route. The drug candidate acts by targeting follicular sulfotransferase (SULT1A1) and being developed as an adjuvant therapy to increase the effect of minoxidil.
Jupiter Wellness overview
Jupiter Wellness a company operates as a pharmaceutical company and the company manufactures products for physical and mental benefits. It is headquartered in Jupiter, Florida, the US.
For a complete picture of AB-103’s drug-specific PTSR and LoA scores, buy the report here.